ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Crossject

Crossject (ALCJ)

1.90
0.002
(0.11%)
Closed July 13 11:30AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.90
Bid
1.882
Ask
1.918
Volume
17,137
1.89 Day's Range 1.918
1.52 52 Week Range 5.96
Market Cap
Previous Close
1.898
Open
1.89
Last Trade
60
@
1.9
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
87,868
Shares Outstanding
36,763,256
Dividend Yield
-
PE Ratio
-13.83
Earnings Per Share (EPS)
-0.24
Revenue
6.51M
Net Profit
-8.64M

About Crossject

Sector
Med, Dental, Hosp Eq-whsl
Industry
Med, Dental, Hosp Eq-whsl
Headquarters
Dijon, Cote-d'or, Fra
Founded
1970
Crossject is listed in the Med, Dental, Hosp Eq-whsl sector of the Euronext with ticker ALCJ. The last closing price for Crossject was 1.90 €. Over the last year, Crossject shares have traded in a share price range of 1.52 € to 5.96 €.

Crossject currently has 36,763,256 shares outstanding. The market capitalization of Crossject is 69.78 € million. Crossject has a price to earnings ratio (PE ratio) of -13.83.

ALCJ Latest News

Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine

Key contribution to the acceleration of the development of ZENEO® EpinephrineFinancial support includes mainly grants, as well as subsidized loansFrance 2030 Plan dedicated to supporting French...

Crossject obtient 6,9 millions d'euros de financement public dans le cadre du plan France 2030, pour accélérer le développement de ZENEO® Adrénaline

Crossject obtient 6,9 millions d'euros de financement public dans le cadre du plan France 2030, pour accélérer le développement de ZENEO® Adrénaline Contribution clé à l'accélération du...

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Dijon, le 5 juillet 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), «...

Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée.

Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée. L'étude de référence...

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Dijon, le 18 juin 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), «...

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Dijon, le 13 juin 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), «...

Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord

Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord Dr Chiche mettra à profit sa vaste expérience en matière de développement de médicaments aux États-Unis et à...

Crossject annonce le vif succès de son augmentation de capital de 8 millions d’euros

Crossject annonce le vif succès de son augmentation de capital de 8 millions d’euros Une levée de fonds d’un montant brut de près de 8 millions d’euros Permet de poursuivre les activités de...

Crossject announces highly successful closing of its €8 million rights offering

Gross fundraising of approximately €8 million or 100% of the planned rights offering as proposed and announced on 30 April 2024 Allows to continue the clinical and regulatory development of...

Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy

  Clinical study performed in 2022 now published in peer-reviewed Neurology and Therapy Further elaborates on bioequivalence demonstrated versus European listed drug Dormicum® Early onset can be...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.2213.09523809521.681.9181.65742591.8624911DE
40.021.063829787231.881.9181.52868111.7048243DE
12-0.15-7.317073170732.052.541.52878681.92345616DE
26-3.8-66.66666666675.75.91.521031322.91677829DE
52-1.8-48.64864864863.75.961.52817853.47054764DE
156-1-34.48275862072.95.961.408865813.36880762DE
2600.0552.98102981031.8455.961.041391163.03188422DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VEVVicinity Motor Corporation
$ 0.7131
(122.15%)
116.26M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
IVPInspire Veterinary Partners Inc
$ 10.52
(88.19%)
41.79M
TOYOTOYO Company Ltd
$ 2.699
(74.13%)
56.65M
NISNNiSun International Enterprise Development Group Company Ltd
$ 9.11
(51.33%)
7.4M
SISIShineco Inc
$ 0.8446
(-60.16%)
6.71M
MCACMonterey Capital Acquisition Corporation
$ 3.54
(-49.50%)
364.7k
MCACUMonterey Capital Acquisition Corporation
$ 7.64
(-28.40%)
2.61k
GENEGenetic Technologies Ltd
$ 0.80
(-27.93%)
780.46k
KZIAKazia Therapeutics Ltd
$ 0.8975
(-27.62%)
25.62M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
MAXNMaxeon Solar Technologies Ltd
$ 0.237
(-1.54%)
286.13M
NVDANVIDIA Corporation
$ 129.24
(1.44%)
251.69M
AGRIAgriFORCE Growing Systems Ltd
$ 0.1001
(21.92%)
192.82M
LCIDLucid Group Inc
$ 4.25
(25.00%)
167.79M

Discussion

View Full Feed
Just the facts maam Just the facts maam 1 minute ago
5.816 million authorized shares left to play with. FYI, they registered 3.07 million shares for the Novitium deal. One or two large deals could eat up much of the remaining authorized share. Unless they no longer need equity financing for business development. I still they will have to issue sha
ANIP
Monksdream Monksdream 1 minute ago
HLT new 52=week high
https://investorshub.advfn.com/uimage/uploads/2024/7/13/qhorqIMG_9536.gif
HLT
condor1 condor1 2 minutes ago
Then is it fair to state that you are basing all of your damning claims on only a few facts, suspicions, beliefs, conjecture, and unfounded conclusions?
AABB
janetcanada janetcanada 2 minutes ago
GRST - Quote: "These are the dreams we have to keep believing in"......

👀***Mr. Shawn Leon "Fulfill Achievement" ..... will be "A shareholders "Dream Come True!"......

Great Post!....

***GRST Logically
So from 60 beds to 600 beds.
GRST
mick mick 3 minutes ago
Induction motor /\ Three-phase totally-enclosed fan-cooled (TEFC) induction motor with end cover on the left, and without end cover to show cooling fan on the right. In TEFC motors, interior heat losses are dissipated indirectly through enclosure fins, mostly by forced air convection.

vdog1776 vdog1776 3 minutes ago
Sure buddy!! 👍
VXIT
nwsun nwsun 4 minutes ago
It's on YouTube. It titled " How private equity destroyed America. It's on The Chris Hedges Report. It's an interesting view.
SFLM
Seminole Red Seminole Red 4 minutes ago
BREAKING: Richard Simmons Dead at 76: Report
Dj56 Dj56 5 minutes ago
FOR NEWBIES ONKY....


THE VALUE ADDING PROCESS OF RSPI EMPLOYEE BEHAVIORS CONTINUES AS DOES SHAREHOLDER INCREASING VALUE... REGARDLESS OF ITS STOCK DISPOSITION, PLACEMENT OR PRICE.

VALUE IS VALUE.

INCREASING VALUE IS INCREASING VALUE.
RSPI
Konaploinks Konaploinks 5 minutes ago
Well Doc. Like I’ve said before. I hope you’re right. Something fishy seems to be going on. That’s for sure.
al44 al44 5 minutes ago
Funny why they have Hillary in this meme-

https://media.gettr.com/group6/getter/2024/07/05/20/4362a4d6-2cdd-8d0c-fbc4-e1112eb8d02d/2ef9e39cf49fb2e926196d2bb66787e9_768x0.jpg
Dazoff Dazoff 5 minutes ago
I feel the same way as you Tibby.
TradingCharts TradingCharts 5 minutes ago
PAGE 110

LITHIUM
(Data in metric tons, lithium content, unless otherwise specified)
Domestic Production and Use: Commercial-scale lithium production in the United States was from a continental
brine operation in Nevada and from brine-sourced waste tailings of a
IBATF
hedge_fun hedge_fun 6 minutes ago
Glad we agree, but are you qualified…..

to make that determination?

What makes someone an expert?

16 years of failure after issuing 8B shares and spending almost $30MM?

Be specific.

TIA
SFRX
NoMoDo NoMoDo 7 minutes ago
Not sure what makes me a shill, but my first purchase of that particular stock was May 8th. I bought at an average of $5.38. There was no ihub board for this particular stock, so in June, I decided to make one. Hate doing that because after the stock looks spent, I really won't care about managin
HMBL
JJ8 JJ8 8 minutes ago
Intel share price still in Breakout mode.

Planning to add more share should price be around and lower the $34 level.

Cheers & GLTA
INTC
Eli's Gone Eli's Gone 8 minutes ago
I always liked Torrens---the Yanks really didn't have much of a choice in keeping him as he had a clause in his contract in that if he wasn't in the majors by June 15th, he could ask for a release---and with Trevino and Wells on the 25, Torrens was gonna be lost so we took some dough for him---Rortv
Konaploinks Konaploinks 9 minutes ago
Then go on chat and read his attorney’s briefs. Jeez. It’s all out there. Same on chit. He has nothing new to appeal over his last denied appeal. Go look or ask your bots.
Seemee44 Seemee44 9 minutes ago
Thanks for sharing..,
Off on strike now & let's run north..
LTNC
frrol frrol 9 minutes ago
Lol. But there's no pill for foolish.
AVXL
douginil douginil 10 minutes ago
Nice Find Gman, Thanks for posting
NB
capgain capgain 11 minutes ago
That would work IMO.

Your Recent History

Delayed Upgrade Clock